** Shares of drug developer Skye Bioscience SKYE.O rise 11.5% to $1.46 premarket
** Co says its drug candidate, nimacimab, showed 23.5% weight loss in mice, comparable to Eli Lilly's LLY.N popular drug, tirzepatide, sold as Zepbound, and Novo Nordisk's NOVOb.CO experimental drug, monlunabant
** SKYE also says nimacimab, when combined with tirzepatide, showed a greater than 30% weight loss
** Initial data from SKYE's mid-stage study in obesity is expected in late Q3/early Q4 2025
** Up to last close, stock had fallen 53.7% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。